Benitec Biopharma Inc. Common Stock

BNTCNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
13.13 USD
↗ 0.44 (3.47%)AT CLOSE (11:59 AM EDT)
13.15
↗ 0.01 (0.11%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
13.15
↗ 0.01 (0.11%)
🔴Market: CLOSED

BNTC is currently priced at $13.13. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest BNTC is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Aug 6, 2026.

Open?$12.71
High?$13.33
Low?$12.71
Prev. Close?$12.69
Volume?82.9K
Avg. Volume?125.8K
VWAP?$13.08
Rel. Volume?0.66x
Bid / Ask
Bid?$12.00 × 100
Ask?$14.00 × 700
Spread?$2.00
Midpoint?$13.00
Valuation & Ratios
Market Cap?436.0M
Shares Out?34.4M
Float?21.1M
Float %?61.4%
P/E Ratio?N/A
P/B Ratio?2.38
EPS?-$1.42
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
19
Market Cap
436.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.benitec.com
Listed
2012-07-11
Address
3940 TRUST WAY
HAYWARD, CA 94545
Phone: (510) 780-0819
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?69.58Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?10.76%High
Short Interest?2.3M
Days to Cover?23.5
Free Float21.1M
Avg Daily Volume96.7K
Settlement Date2026-07-15
Financial Health
Current Ratio?56.82Strong
Quick Ratio?56.82Strong
Cash Ratio?56.43Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
66
2.38CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-26.7%WEAK▾
ROA?
S&P
3
-26.1%WEAK▾
Cash Flow & Enterprise
FCF?$-19818000
Enterprise Value?$251.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist